Please login to the form below

Not currently logged in
Email:
Password:

Vertex Pharma

This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.

Reshma Kewalramani joins Vertex Pharmaceuticals as CMO

Reshma Kewalramani joins Vertex Pharmaceuticals as CMO

Vertex Pharmaceuticals, a biotech known for its clinical development programmes in cystic fibrosis, has appointed a new chief medical officer in the form of Reshma Kewalramani. ... Jeffrey Leiden, chairman, president and chief executive officer of Vertex,

Latest news

  • Vertex's two-drug cystic fibrosis treatment cleared in US Vertex's two-drug cystic fibrosis treatment cleared in US

    Vertex's two-drug cystic fibrosis treatment cleared in US. FDA approves Symdeko, which combines Kalydeco and tezacaftor. ... Vertex Pharma has won an FDA green light for a third product for cystic fibrosis, and its second combination therapy for the

  • Vertex's tezacaftor/ivacaftor shows lung function boost Vertex's tezacaftor/ivacaftor shows lung function boost

    Vertex's tezacaftor/ivacaftor shows lung function boost. The combination therapy is currently under review in Europe and the US. ... US biotech Vertex has revealed positive phase III results of its tezacaftor/ivacaftor treatment for the underlying cause

  • FDA broadens use of cystic fibrosis drug Kalydeco FDA broadens use of cystic fibrosis drug Kalydeco

    Vertex Pharma is celebrating after the FDA once again extended the labelling for its cystic fibrosis therapy Kalydeco so that more patients with the genetic disease are eligible to use it. ... Vertex says the new labelling - which was initially turned

  • Merck pays Vertex $230m upfront for cancer programmes Merck pays Vertex $230m upfront for cancer programmes

    Merck pays Vertex $230m upfront for cancer programmes. Licences four DNA damage and repair programmes with first-in-class or best-in-class potential. ... Merck KGaA has licensed four DNA damage and repair programmes from Vertex Pharma that it says will

  • Vertex' cystic fibrosis drug too costly, says NICE Vertex' cystic fibrosis drug too costly, says NICE

    Vertex' cystic fibrosis drug too costly, says NICE. £104, 000 per patient price tag is "too high" for the drug’ s “ modest” short term benefit. ... Vertex Pharma's cystic fibrosis (CF) drug Orkambi will not be made available on the NHS in England

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • The challenges of making genomics a reality for patients today, not tomorrow The challenges of making genomics a reality for patients today, not tomorrow

    The report singles out Vertex among a handful of successful biotech companies with highly innovative products. ... Dr Gillian Burgess is site head of UK Research and Vice President at Vertex.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    For an indepth analysis of these deals, read'Pharma deals during November 2014'. ... Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Reckitt Benckiser(RB) is spinning out its pharma business unit, under the name Indivior. ... On a mission. Continuing its trend of helping companies monetise their future income streams, Royalty Pharma is buying royalties in Vertex Pharmaceutical's

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • BMS appoints three independent directors BMS appoints three independent directors

    Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Random42 Scientific Communication

    Collegium Pharmaceutical. CSL Behring. Dainippon Sumitomo Pharma. Daiichi-Sankyo. DePuy Synthes. DBV Technologies . ... Unilever. Vasopharm. Vertex. Vetoquinol. Vifor Pharma. VR1 Inc. Wyss Center. Xenetic Biosciences.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics